{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-019249","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2022-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.127907+00:00","generated_at":"2026-06-24T10:36:17.438312+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023","bullets":["Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.","FY2022 gross margin improved to 52% (from 48%); adjusted EBITDA $3.1M vs $2.1M.","Operating income $607K for FY2022; cash $9.0M, no debt.","Guidance: projects another year of top-line growth of ~20% for FY2023.","CEO notes expanding ex-vivo services and computational discovery tools moving to preclinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-019249","json":"https://secwatch.observer/filing/0001628280-22-019249.json","markdown":"https://secwatch.observer/filing/0001628280-22-019249.md","text":"https://secwatch.observer/filing/0001628280-22-019249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828022019249/0001628280-22-019249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828022019249/csbr8-k4302022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T10:36:17.438312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}